We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: del(17p)
MedXY News
EnglishTag

del(17p)

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligenceclinical trialstype 1 diabetesHypertensiononcologyCardiologypublic healthdiabetesMortalitycardiovascular diseaseAlzheimer's diseasebreast cancerepidemiology

Latest news

Tag

Targeting ROR1 in Chronic Lymphocytic Leukemia: Insights from the Zilovertamab and Ibrutinib Combination in High-Risk del(17p) Disease
Hematology-OncologyBệnh bạch cầu lympho mạn tính dòng B (Chronic Lymphocytic Leukemiadel(17p)

Targeting ROR1 in Chronic Lymphocytic Leukemia: Insights from the Zilovertamab and Ibrutinib Combination in High-Risk del(17p) Disease

By MedXY|Oct 6, 2026

A phase 1b/2 study evaluating zilovertamab combined with ibrutinib in relapsed/refractory CLL reveals safety, mechanistic inhibition of ROR1 signaling pathways, and a potential efficacy signal in del(17p) patients warranting further studies

Targeting PKMYT1: A Promising Therapeutic Strategy for High-Risk del(17p) Multiple Myeloma
Hematology-Oncologytargeted therapy
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
del(17p)

Targeting PKMYT1: A Promising Therapeutic Strategy for High-Risk del(17p) Multiple Myeloma

By MedXY|Sep 22, 2026

PKMYT1 inhibition emerges as a selective and effective therapeutic approach against del(17p) high-risk multiple myeloma by inducing lethal DNA damage and mitotic failure.

Genetic Risk and Ibrutinib Treatment Outcomes in Early-Stage CLL: Insights from the GCLLSG CLL12 Trial
Hematology-OncologyIbrutinibgenetic risk factors

Genetic Risk and Ibrutinib Treatment Outcomes in Early-Stage CLL: Insights from the GCLLSG CLL12 Trial

By MedXY|Sep 1, 2026

The GCLLSG CLL12 trial reveals ibrutinib’s event-free survival benefits in specific genetic subgroups of early-stage CLL, while affirming watch-and-wait as standard for high-risk patients with del(17p) and TP53 mutations.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models